Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists

Journal of Medicinal Chemistry

Volumn 50, Issue 1, 2007, Pages 21-39

  Kaila, Neelu ^a   Janz, Kristin ^a   DeBernardo, Silvano ^a   Bedard, Patricia W ^a   Camphausen, Raymond T ^a,b   Tam, Steve ^a   Tsao, Desirée H H ^a   Keith Jr , James C ^a   Nickerson Nutter, Cheryl ^a   Shilling, Adam ^a   Young Sciame, Ruth ^a   Wang, Qin ^a  

^a PFIZER INC   (United States)

^b Adnexus Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 CHLOROPHENYL) 3 HYDROXY 8 PHENYLQUINOLINE 4 CARBOXYLIC ACID; CARRAGEENAN; CYTOCHROME P450; DIHYDROOROTATE DEHYDROGENASE; DIHYDROOROTATE DEHYDROGENASE INHIBITOR; GLYCOPROTEIN; PADGEM PROTEIN; PROTEIN INHIBITOR; QUINOLINE DERIVATIVE; SALICYLIC ACID DERIVATIVE; SIALYL LEWIS X ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CELL ASSAY; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOTHELIUM CELL; ENZYME INHIBITION; EVALUATION; INFLAMMATION; LEUKOCYTE ADHERENCE; LEUKOCYTE ROLLING; MALE; NONHUMAN; NUCLEAR OVERHAUSER EFFECT; PAW EDEMA; PROTEIN PROTEIN INTERACTION; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; RHEUMATOID ARTHRITIS; STRUCTURE ANALYSIS;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 ENZYME SYSTEM; DATABASES, FACTUAL; EDEMA; HUMANS; HYDROXYQUINOLINES; LEUKOCYTE ROLLING; MALE; P-SELECTIN; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; SALICYLIC ACIDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33846217395     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0602256     Document Type: Article

References (62)

1. Springer, T. A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994, 76, 301-314.
2. Thorlacius, H. Selectins as targets in inflammatory diseases. Curr. Med. Chem. Anti-Inflammatory Anti-Allergy Agents 2004, 3, 31-38.
3. (a) McMurray, R. W. Adhesion Molecules in Auto Immune Disease. Semin. Arthritis Rheum. 1996, 25, 215-233.
4. (b) Hosaka, S.; Shah, M. R.; Pope, R. M.; Koch, A. E. Soluble forms of P-selectin and intercellular adhesion molecule-3 in synovial fluids. Clin. Immunol. Immunopathol. 1996, 78, 276-282.
5. Robinson, D. S.; Frenette, P. S.; Rayburn, H.; Cummiskey, M.; Ullman-Culleré, M.; Wagner, D. D.; Hynes, R. O. Multiple, targeted deficiencies in selectins reveal a predominant role for P-selectin in leukocyte recruitment. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 11452-11457.
6. x-mimicking selectin inhibitors: design, synthesis and crystal structure in complex with E-selectin. J. Med. Chem. 2005, 48, 4346-4357.
7. Kaila, N.; Chen, L.; Thomas, B. E., IV; Tsao, D.; Tam, S.; Bedard, P. W.; Camphausen, R. T.; Alvarez, J. C.; Ullas, G. Beta-C-mannosides as selectin inhibitors. J. Med. Chem. 2002, 45, 1563-1566.
8. Gasser, M.; Waaga-Gasser A. M.; Grimm, M. W.; Grimm, M. R.; Lenhard, M. S.; Krist-Van Holthe, J. E.; Laskowski, I.; Shaw, G. D.; Thiede, A.; Hancock, W. W.; Tilney, N. L. Selectin blockade plus therapy with low-dose sirolimus and cyclosporin a prevent brain death-induced renal allograft dysfunction. Am. J. Transplant. 2005, J, 662-670.
9. Seekamp, A.; van Griensven, M.; Dhondt, E.; Diefenbeck, M.; Demeyer, I.; Vundelinckx, G.; Haas, N.; Schaechinger, U.; Wolowicka, L.; Rammelt, S.; Stroobants, J.; Marzi, I.; Brambrink, A. M.; Dziurdzik, P.; Gasiorowski, J.; Redl, H.; Beckert, M.; Khan-Boluki, J. The effect of anti-L-selectin (aselizumab) in multiple traumatized patients - results of a phase II clinical trial. Crit. Care Med. 2004, 32, 2021-2028.
10. (a) Alper, J. Searching for medicines sweet spot. Science 2001, 291, 2338-2343.
11. (b) Kerr, K. M.; Auger, W. R.; Marsh, J. J.; Commito, R. M.; Fedullo, R. L.; Smits, G. J.; Kapelanski, D. P.; Fedullo, P. F.; Channick, R. N.; Jamieson, S. W.; Moser, K. M. The use of cylexin (CY-1503) in prevention of reperfusion lung injury in patients undergoing pulmonary thromboendarterectomy. Am. J. Respir. Crit. Care Med. 2000, 162, 14-20.
12. (a) Aydt, E.; Wolff, G. Development of synthetic pan-selectin antagonists: a new treatment strategy for chronic inflammation in asthma. Pathobiology 2003, 70, 297-301.
13. (b) Romano, S. J., Selectin antagonists: therapeutic potential in asthma and COPD. Treat. Respir. Med. 2005, 4, 85-94
14. Slee, D. H.; Romano, S.; Yu, J.; Nguyen, T. N.; John, J. K.; Raheja, N. K.; Axe, F. U.; Jones, T. K.; Ripka, W. C. Development of potent non-carbohydrate imidazole-based small molecule selectin inhibitors with antiinflammatory activity. J. Med. Chem. 2001, 44, 2094-2107.
15. Ohta, S.; Inujima, Y.; Abe, M.; Uosaki, Y.; Sato, S.; Miki, I. Inhibition of P-selectin specific cell adhesion by a low molecular weight, non-carbohydrate compound, KF38789. Inflammation Res. 2001, 50, 544-551.
16. Schön, M. P.; Krahn, T.; Schön, M.; Rodriguez, M.-L.; Antonicek, H.; Schultz, J. E.; Ludwig, R. J.; Thomas, M.; Zollner, T. M.; Bischoff, E.; Bremm, K.-D.; Schramm, M.; Henninger, K.; Kaufmann, R.; Gollnick, H. P. M.; Parker, C. M.; Boehncke, W.-H. Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation. Nature Med. 2002, 8, 366-372.
17. Bendas, G. Inhibitors of membrane receptors involved with leukocyte extravasation. Mini-Rev. Med. Chem. 2005, 5, 575-584.
18. The ELISA evaluates the binding of a PSGL-1 fusion protein, which consists of the functional N-terminal region of PSGL-1 fused to the Fc region of IgG1, to immobilized soluble P-selectin, which is preincubated with the test compound.
19. (a) Simanek, E. E.; McGarvey, G. J.; Jablonowski, J. A.; Wong, C.-H. Selectin-Carbohydrate Interactions: From Natural ligands to designed mimics. Chem. Rev. 1998, 98, 833-862.
20. (b) Kaila, N.; Thomas, B. E., IV. Design and synthesis of sialyl Lewis x mimics as E- and P-selectin inhibitors. Med. Res. Rev. 2002, 22, 566-601.
21. x and PSGL-1. Cell 2000, 103, 467-479.
22. Thoma, G.; Patton, J. T.; Magnani, J. L.; Ernst, B.; Ohrlein, R.; Duthaler, R. O. Versatile functionalization of polylysine: synthesis, characterization, and use of neoglycoconjugates. J. Am. Chem. Soc. 1999, 121, 5919-5929.
23. Kaila, N.; Chen, L.; Thomas, B. E., IV; Tsao, D.; Tam, S.; Bedard, P. W.; Camphausen, R. T.; Alvarez, J. C.; Ullas, G. β-C-Mannosides as selectin inhibitors. J. Med. Chem. 2002, 45, 1563-1566.
24. x tetrasaccharide, free in solution and bound to E-, P-, and L-selectin. J. Am. Chem. Soc. 1997, 119, 1727-1736.
25. (b) Ni, F. Recent developments in transferred NOE methods. Prog. Nucl. Magn. Reson. Spectrosc. 1994, 26, 517-606.
26. (c) Meyer, B.; Thomas, W.; Peters, T. Screening mixtures for biological activity by NMR. Eur. J. Biochem. 1997, 246, 705-709.
27. x mimetics as potential selectin antagonists. Tetrahedron 1997, 53, 2485-2494.
28. (a) Cragoe, E. J.; Robb, C. M.; Bealor, M. D. The synthesis of 3-hydroxycinchoninic acid and certain of its derivatives. J. Org. Chem. 1953 18, 552-560.
29. (b) Cragoe, E. J.; Bealor, M. D.; Robb, C. M.; Ziegler, C.; Sprague, J. M. The synthesis of 3-hydroxy-2-phenylquinoline-4,8-dicarboxylic acid and certain of its derivatives. J. Org. Chem. 1953, 18, 561-569.
30. (a) Sandmeyer, T. Isonitrosoacetanilides and their condensation to form isatin derivatives. Helv. Chim. Acta. 1919, 2, 234-242.
31. (b) Yang, K.; Campbell, B.; Birch, G.; Williams, V. E.; Lemieux, R. P. Induction of a ferroelectric Sc* liquid crystal phase by an atropisomeric dopant derived from 4,4′-dihydroxy-2,2′-dimethyl-6,6′- dinitrobiphenyl. J. Am. Chem. Soc. 1996 118, 9557-9561.
32. (c) Marvel, C. S.; Hiers, G. S. Isatin Org. Synth. 1925, V, 71-74.
33. Cook, J. W.; Loudon, J. D.; McCloskey, P. The chemistry of the Mitragyna genus. J. Chem. Soc. 1952, 3904-3912.
34. Lisowski, V.; Robba, M.; Rault, S. Efficient synthesis of novel 3-(het)arylanthranilic acids via a Suzuki cross-coupling reaction of 7-iodoisatin with (het)arylboronic acids in water. J. Org. Chem. 2000, 65, 4193-4194.
35. Diwu, Z.; Beachdel C.; Klaubert, D. H. A facile protocol for the convenient preparation of amino-substituted α-bromo- and α,α-dibromo arylmethyl ketones Tetrahedron Lett. 1998, 39, 4987-4990.
36. 5
37. This compound was studied as an anti-inflammatory agent at Lederle.
38. Pally, C.; Smith, D.; Jaffee, B.; Magolda, R.; Zehender, H.; Dorobek, B.; Donatsch, P.; Papageorgiou, C.; Schuurman, H.-J. Side effects of brequinar and brequinar analogues, in combination with cyclosporine, in the rat. Toxicology 1998, 127, 207-222.
39. (a) Neidhardt, E. A.; Punreddy, S. R.; McLean, J. E.; Hedstrom, L.; Grossman, T. H. Expression and characterization of E. coli-produced soluble, functional human dihydroorotate dehydrogenase: a potential target for immunosuppression J. Mol. Microbiol. Biotechnol. 1999, 1, 183-188.
40. (b) Knecht, W.; Bergjohann, U.; Gonski, S.; Kirschbaum, B.; Loffler, M. Functional expression of a fragment of human dihydroorotate dehydrogenase by means of baculovirus expression vector system, and kinetic investigation of purified recombinant enzyme. Eur. J. Biochem. 1996, 240, 292-301.
41. 50s from cell interaction assays are lower and more biologically relevant because they incorporate physiological flow rates and selectin densities and are under nonequilibrium conditions.
42. Bendele, A.; McComb, J.; Gould, T.; McAbee, T.; Sennello, G.; Chlipala, E.; Guy, M. Animal models of arthritis: relevance to human disease. Toxicol. Pathol. 1999, 27, 34-142.
43. This animal model has been used to demonstrate the antiarthritic potential of agents such as methotrexate or nonsteroidal antiinflammatory agents (NSAIDS). Kerwar, S. S.; Oronsky, A. L. Methotrexate in rheumatoid arthritis: studies with animal models. Adv. Enzyme Regul. 1989, 29, 247-265.
44. Walter, U. M.; Issekutz, A. C. The role of E- and P-selectin in neutrophil and monocyte migration in adjuvant-induced arthritis in the rat. Eur. J. Immunol. 1997, 27, 1498-1505.
45. Kumar, A.; Villani, M. P.; Patel, U. K.; Keith, J. C., Jr.; Schaub, R. G. Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model. Circulation 1999, 99, 1363-1369.
46. Khor, P. S.; Mccarthy, K.; Dupont, M.; Murray, K.; Timony, G. Pharmacokinetics, pharmacodynamics, allometry, and dose selection of rPSGL - Ig for phase I trial. J. Pharmacol. Exp. Ther. 2000, 293, 618-624.
47. Kogan, T. P.; Dupre, B.; Bui, H.; McAbee, K. L.; Kassir, J. M.; Scott, I. L.; Hu, X.; Vanderslice, P.; Beck, P. J.; Dixon, R. A. F. Novel Synthetic inhibitors of selectin-mediated cell adhesion: synthesis of 1,6-bis[3-(3- carboxymethylphenyl)-4-(2-α-D-mannopyranosyloxy)phenyl]hexane (TBC1269). J. Med. Chem. 1998, 41, 1099-1111.
48. Abraham, W. M.; Ashfaq Ahmed, A.; Sabater, J. R.; Lauredo, I. T.; Botvinnikova, Y.; Bjercke, R. J.; Hu, X.; Revelle, M. B.; Kogan, T. P.; Scott, I. L.; Dixon, R. A. F.; Yeh, E. T. H.; Beck, P. J. Selectin blockade prevents antigen-induced late bronchial responses and airway hyperresponsiveness in allergic sheep. Am. J. Respir. Crit. Care Med. 1999, 159, 1205-1214.
49. Langer, R.; Wang, M.; Stepkowski, S. M.; Hancock, W. W.; Han, R.; Li, P.; Feng, L.; Kirken, R. A.; Berens, K. L.; Dupre, B.; Podder, H.; Dixon, R. A. F.; Kahan, B. D. Selectin inhibitor bimosiamose prolongs survival of kidney allografts by reduction in intragraft production of cytokines and chemokines. J. Am. Soc. Nephrol. 2004, 15, 2893-2901.
50. Otterness, I. G.; Bliven, M. L. Nonsteroidal Anti-Inflammatory Drugs. Chemistry and Pharmacology of Drugs; Wiley: New York, 1985; Vol. 5. pp 111-252.
51. Deady, L. W.; Desneves, J.; Kaye, A. J.; Finlay, G. J.; Baguley, B. C.; Denny, W. A. Positioning of the carboxamide side chain in 11-oxo-11H- indeno[1,2-b]quinolinecarboxamide anticancer agents: effects on cytotoxicity. Bioorg. Med. Chem. 2001, 9, 445-452.
52. Rewcastle, G. W.; Atwell, G. J.; Zhuang, L.; Baguley, B. C.; Denny, W. A. Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J. Med. Chem. 1991, 34, 217-222.
53. Dierks, E. A.; Stams, K. R.; Lim, H.; Cornelius, G.; Zhang, H.; Ball, S.E. A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab. Dispos. 2001, 29, 23-29.
54. (a) Goetz, D. J.; Greif, D. M.; Ding, H.; Camphausen, R. T.; Howes, S.; Comess, K. M.; Snapp, K. R.; Kansas, G. S.; Luscinskas, F. W. Isolated P-selectin glycoprotein ligand-1 dynamic adhesion to P- and E-selectin. J. Cell Biol. 1997, 137, 509-519.
55. (b) Sako, D.; Comess, K. M.; Barone, K. M.; Camphausen, R. T.; Cumming, D. A.; Shaw, G. D. A sulfated peptide segment at the amino terminus of PSGL-1 is critical for P-selectin binding. Cell 1995, 83, 323-331.
56. Myszka, D. G. Improving biosensor analysis. J. Mol. Recognit. 1999, 12, 279-284.
57. Winter, C. A.; Risley, E. A.; Nuss, G. W. Carrageenan-induced edema in hind paw of rat as an assay for antiinflammatory drugs. Proc. Soc. Exp. Biol. Med. 1962, 111, 544-547.
58. Keith, J. C., Jr.; Albert, L. M.; Leathurby, Y.; Follettie, M.; Wang, L.; Borges-Mancucci, L.; Chadwick, C. C.; Steffan, R. J.; Harnish, D. C. The identification of pathway selective estrogen receptor ligands which inhibit NF-κB transcriptional activity and their utility in RA. Arthritis Res. Ther. 2005, 7, R427-R438.
59. Steffan, R. J.; Matelan, E.; Ashwell, M. A.; Moore, W. J.; Solvibile, W. R.; Trybulski, E.; Chadwick, C. C.; Chippari, S.; Kenny, T.; Eckert, A.; Borges-Marcucci, L.; Keith, J. C., Jr.; Xu, Z.; Mosyak, L.; Harnish, D. C. Synthesis and activity of substituted 4-(indazol-3-yl)-phenols as pathway selective estrogen receptor ligands useful in the treatment of rheumatoid arthritis. J. Med. Chem. 2004, 47, 6435-6538.
60. Zhang, Y.; Hegen, M.; Xu, J.; Keith, J. C., Jr.; Jin, G.; Du, X.; Cummons, T.; Sun, L. H.; Zhu, Y.; Rao, V. R.; Wang, Q.; Xu, W.; Cowling, R.; Nickerson-Nutter, C. L.; Gibbons, J.; Skotnicki, J.; Lin, L. L.; Levin, J. Characterization of (2R,3S)-2-({4-(2-butynyloxy0phenyl]-sulfonyl} amino)-N-3-dihydroxybutanamide (TMI-2), a potent and selective inhibitor of TNF-α converting enzyme (TACE). Int. J. Immunopharmacol. 2004, 4, 1845-1857.
61. Follettie, M. T.; Pinard, M.; Keith, J. C., Jr.; Paramithiotis, E.; Wang, L.; Chelsky, D.; Butler, H.; Kearney, P.; Hui, J.; Plante, S.; Thibaudeau, E.; Chan, D.; Thibault, P.; Dorner, A.; Harris, H. A. Plasma proteome and organ mRNA changes in the adjuvant-induced arthritis model: responses to disease induction and therapy with ERB-041. Endocrinology 2005, Epub November 3.
62. Mewshaw, R. E.; Edsall, R. J., Jr.; Yang, C.; Manas, E. S.; Xu, Z. B.; Henderson, R. A.; Keith, J. C., Jr.; Harris, H. A. ERβ ligands. 3. Exploiting two binding orientations of the 2-phenyl-naphthalene scaffold to achieve ERβ selectivity. J. Med. Chem. 2005, 48, 3953-3979.